Tackling Worldwide Drugs of Abuse
Tackling Worldwide Drugs of Abuse
Throughout November, we’ve been highlighting how the Randox clinical teams – Randox Rx series, Randox Reagents and Randox QC – are aiding the fight against drugs of abuse.
Drugs of Abuse are a growing problem worldwide and represent a significant burden to healthcare systems as well as creating problems in an individual’s lifestyle. It has been estimated by the WHO (World Health Organisation) that 31 million people globally suffer from drug use disorders and 3.3 million deaths each year are linked to the abuse of both drugs and alcohol.
The abuse of drugs is one of the most pressing issues in the United States of America. Drug abuse not only affects the individual, but also can have far-reaching consequences that affect family, employment, personal health, health care systems, local communities, and society as a whole.
- Misuse of illicit drugs affects society through secondary costs incurred such as crime, reduced productivity at work, and health care expenses.
- Substance abuse costs the US health care system about $11 billion, with overall costs reaching $193 billion.
- Substance abuse and addiction also affects other areas of life and can cause broken families, destroyed careers, death due to negligence or accident, domestic violence, physical abuse and child abuse.
- Drug abuse and addiction changes the chemistry of your brain. The longer you use your drug of choice, the more damage is caused and it becomes more difficult to return to ‘normal’ during drug rehabilitation.
- In 2013, 22.7 million Americans needed treatment for a substance use disorder – almost 9% of the population over the age of 12. Only about 2.5 million received treatment as a specialist facility with 20% of admissions for opiate addication treatment and 17% for the treatment of marijuana abuse.
To find out more about how Randox is helping in the fight against Drugs of Abuse, please visit https://www.randox.com/drugs-of-abuse/ or for more information about Randox RX, Randox Reagents or Randox QC, please email marketing@randox.com.
November focus: Drugs of Abuse
Throughout November, the Randox clinical teams – Randox Reagents, Randox Rx series and Randox QC – will be highlighting how the Randox product range can be utilised to allow for the most accurate analysis of Drugs of Abuse, with a particular focus placed with the Evidence MultiSTAT. The Evidence MultiSTAT is a fast, fully automated and versatile immunoanalyser that enables on-site detection of up to 21 Drugs of Abuse from a single sample of oral fluid, urine or blood.
Drugs of Abuse are a growing problem worldwide and represent a significant burden to healthcare systems as well as creating problems in an individual’s lifestyle. It has been estimated by the WHO (World Health Organisation) that 31 million people globally suffer from drug use disorders and 3.3 million deaths each year are linked to the abuse of both drugs and alcohol.
Randox have reacted to this growing concern and are now a world leader in the Drugs of Abuse testing field. Our product range currently comprises classical, prescription and synthetic drugs.
The Evidence MultiSTAT offers a simple drug screening solution to those who have little or no knowledge of laboratory procedures. As an extremely versatile desktop analyser, it is ideally suited to a variety of settings including both the clinical laboratory and the emergency room.
Randox Reagents – Drugs of Abuse Assays
In order to assist in dealing with the ongoing burden of substance abuse, Randox Reagents offer a comprehensive range of ten assays to test for some of the top most commonly-abused substances including alcohol, methamphetamines, cocaine, methadone, cannabis, benzodiazepines, barbiturates, EDDP and ecstasy and opiates. The Randox Drugs of Abuse assays are liquid, ready-to-use for increased efficiency and applications are available for over 30 different analysers.
RX Series – Toxicology testing
Renowned for quality and reliability, the RX series range of clinical chemistry analysers boasts a world-leading test menu comprising of both therapeutic drugs and Drugs of Abuse. Our toxicology range comprises amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolite, ecstasy, EDDP, ethanol, methadone and opiates. The RX series range of clinical chemistry analysers ensures a high degree of accuracy with a wide range of testing throughputs to suit all laboratories, big or small.
RIQAS Urine Toxicology Programme
Designed to monitor the performance of 20 Drugs of Abuse tests in urine, our RIQAS urine toxicology EQA program is suitable for both qualitative and quantitative methods of analysis. As the largest EQA scheme in the world, access to large peer groups is guaranteed. Additional benefits include; monthly analysis, user-friendly reports allowing at-a-glance performance assessment, ability to register up to five instruments per programme and cost savings via our unrivalled consolidation.
For more information about Randox RX, Randox Reagents or Randox QC, please email marketing@randox.com.
The Evidence Series: What is it and how is it changing the diagnostic landscape forever?
Having developed the patented Biochip Array Technology following £250 million investment in diagnostic research and development, we needed a platform that allowed Biochip Array Technology capabilities to be showcased. Step forward the Evidence Series.
The series includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser has been designed and built with boundary pushing engineering, to ensure financial, labour and time savings for the end user.
Have a read below of the overview of each analyser in the Evidence Series
Evidence Evolution
The world’s first fully automated random-access biochip testing platform, the Evidence Evolution is the world’s most advanced immunoanalyser. With the capability to process up to 2,640 tests per hour, the Evidence Evolution offers complete system integration, as well as the most comprehensive test menu on the market.
Evidence
As the world’s first Biochip Array Technology system, the Evidence immunoanalyser has revolutionised laboratory screening worldwide. With the capability to process 3,960 tests per hour and a sample capacity of 360, the Evidence is ideal for use in a high throughput laboratory.
Evidence Investigator
The Evidence Investigator is a compact, semi-automated benchtop immunoanalyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, toxicology and food diagnostics. The Evidence Investigator boasts a throughput of up to 2,376 tests per hour, offering efficiency without compromising on accuracy.
Evidence MultiSTAT
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. With a three-step process and results generated in less than 20 minutes, the Evidence MultiSTAT is an ideal solution for those with no knowledge of laboratory procedures and offers a throughput of up to 132 tests per hour.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on any of the Evidence Series analysers, please visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Powering the Evidence Series – Biochip Array Technology
In 2002, Randox invented a worlds first; Biochip Array Technology, instantly changing the landscape of diagnostic testing forever. Biochip Array Technology is a multi-analyte platform which provides an unrivalled increase in patient information per sample. Instead of a patient sample needing to be subdivided for each test result, or in some cases re-collected, Biochip Array Technology offers a diagnostic patient profile with each patient sample.
How does it work?
Biochip Array Technology is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
The biochip detection system is based on a chemiluminescent reaction. This is the emission of light, without heat, as a result of a chemical reaction. An enzyme is used to catalyse the chemical reaction on the biochip which generates the chemiluminescent signal. The light emitted from the chemiluminescent reaction that takes place in each DTR is simultaneously detected and quantified using a Charge-Coupled Device (CCD) Camera.
Each biochip has up to 49 Discrete Test Regions (DTR). This means that up to 44 tests can be carried out simultaneously. The additional DTR are reserved for internal quality control and visual reference, a unique Biochip Array Technology feature.
How is the technology applied?
With over £250 million invested into Biochip Array Technology research and development, Randox have launched a range of Biochip Array Technology immunoanalysers – The Evidence Series. This includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser is developed with boundary pushing engineering, designed to make financial, labour and time savings for the end user.
The Evidence Series has truly revolutionised diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on any of the Evidence Series, please visit http://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Evidence Series Immunoanalysers
Powered by Biochip Array Technology
In 2002, Randox invented a world first, Biochip Array Technology (BAT), instantly changing the landscape of diagnostic testing forever. BAT is a multi-analyte platform which provides an unrivaled increase in patient information per sample. Instead of a patient sample needing to be subdivided for each test result, or in some cases re-collected, Biochip Array Technology offers a diagnostic patient profile with each patient sample. So now the patient’s needs become the focus, as BAT delivers the multiple results needed for improved diagnosis.
With over £250 million invested into Biochip Array Technology research and development, Randox have launched a range of Biochip Array Technology immunoanalysers – The Evidence Series. This includes the Evidence, the Evidence Investigator and the Evidence MultiSTAT. Each analyser is developed with boundary pushing engineering, designed to make financial, labour and time savings for the end user. Utilising this technology, the Evidence series guarantees cost-effective, highly accurate and flexible testing solutions.
Click on the immunoanalysers below for more information
Evidence Investigator
Evidence MultiSTAT
Evidence
Why choose the Evidence Series?
Biochip Array Technology Test Menu
Adhesion Molecules
| E-Selectin | P-Selectin | L-Selectin | |
| Intercellular Adhesion Molecule-I – ICAM-I | Vascular Cell Adhesion Molecule-I –VCAM-I | ||
Alzheimer’s
| Apolipoprotein E4 –ApoE4 | Pan Apolipoprotein E – Apo E |
Anaemia
| Ferritin | Folate | Vitamin B12 |
Bone Disease
| Vitamin D | |||
Cancer
| Carcinoembryonic Antigen – CEA | Free Prostate Specific Antigen − FPSA | Total Prostate Specific Antigen − TPSA | |
Cardiac
| Cardiac Troponin I – cTnl | Creatine Kinase MB – CKMB | Heart Fatty Acid Binding Protein – H-FABP | Myoglobin |
Cerebral
| Brain-Derived Neurotrophic Factor − BDNF | Neuron Specific Enolase − NSE | ||
Cytokines
| Epidermal Growth Factor − EGF | Granulocyte Macrophage Colony Stimulating Factor | Interferon-γ − IFN-γ | Interleukin-1 alpha − IL-1α |
| Interleukin-1 beta − IL-1β | Interleukin-2 − IL-2 | Interleukin-3 − IL-3 | Interleukin-4 − IL-4 |
| Interleukin-5 − IL 5 | Interleukin-6 − IL-6 | Interleukin-7 − IL-7 | Interleukin-8 − IL-8 |
| Interleukin-4 − IL-4 | Interleukin-5 − IL 5 | Interleukin-6 − IL-6 | Interleukin-7 − IL-7 |
| Interleukin-8 − IL-8 | Interleukin-10 − IL-10 | Interleukin-12p70 − IL-12p70 | Interleukin-13 − IL-13 |
| Interleukin-15 − IL 15 | Interleukin-23 − IL-23 | Macrophage Infl ammatory Protein-1α − MIP-1α | Matrix Metalloproteinase 9 − MMP 9 |
| Monocyte Chemotactic Protein-1 − MCP-1 | Soluble IL-2 Receptor Alpha − sIL-2Rα | Soluble IL-6 Receptor − sIL-6R | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 |
| Soluble Tumour Necrosis Factor Receptor 2 − sTNFR2 | Tumour Necrosis Factor-α − TNF-α | Vascular Endothelial Growth Factor − VEGF | |
Diabetes
| Insulin | |||
Endocrine
| Cortisol | Dehydroepiandrosterone-Sulphate- DHEAS | ||
Fertility / Pregnancy
| Estradiol | Follicle Stimulating Hormone − FSH | Luteinizing Hormone − LH | Progesterone |
| Prolactin | Sex Hormone Binding Globulin − SHBG | Testosterone | |
Fibrinolysis
| D-Dimer |
Gastro
| Gastrin 17 – GI7 | Helicobacter pylori – H. pylori | Pepsinogen I – PGI | Pepsinogen II – PGII |
Metabolic
| Adiponectin | Ferritin | Insulin | Leptin |
| Plasminogen Activator Inhibitor − PAI-1 | Resistin |
Renal
| Adiponectin | Complement C3a des Arginine – C3a des Arg | CRP (C-Reactive Protein) | Cystatin C |
| D-Dimer | Epidermal Growth Factor − EGF | Fatty Acid Binding Protein-1 − FABP1 | Interleukin-8 − IL-8 |
| Macrophage Infl ammatory Protein-1α − MIP-1α | Neutrophil Gelatinase – Associated Lipocalin – NGAL | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 | Soluble Tumour Necrosis Factor Receptor 2 − sTNFR2 |
Stroke
| Brain-Derived Neurotrophic Factor − BDNF | D-Dimer | Glial Fibrillary Acidic Protein − GFAP | Glutathione S – Transferase Pi – GSTPi |
| Heart Fatty Acid Binding Protein – H-FABP | Interleukin-6 − IL-6 | Nucleoside Diphosphate Kinase – NDKA | Neuron Specifi c Enolase − NSE |
| Parkinson Protein 7 − PARK-7 | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 | ||
Thyroid
| Anti-Thyroglobulin − Anti-Tg | Anti-Thyroid Peroxidase − Anti-TPO | Free Tri-iodothyronine − FT3 | Free Thyroxine − FT4 |
| Thyroid Stimulating Hormone − TSH | Thyroxine Binding Globulin − TBG | Total Tri-iodothyronine − TT3 | Total Thyroxine − TT4 |
Toxicology
| Amphetamine | Barbiturates | Benzodiazepines I | Benzodiazepines II |
| Buprenorphine | Cannabinoids – THC | Cocaine Metabolite | Dextromethorphan |
| Fentanyl | Ketamine | Meprobamate | Methadone |
| Opiate | Oxycodone I | Oxycodone II | Phencyclidine – PCP |
| Tramadol | Tricyclic Antidepressants | Zolpidem | |
Molecular
| 20 SNPs | Adenovirus A/B/C/D/E | APOB – 1 mutation | Bordetella pertussis |
| BRAF – 1 mutation | Chlamydia trachomatis – (CT) | Chlamydophila pneumoniae | Coronavirus 229E/NL63 |
| Coronavirus OC43/HKU1 | Enterovirus A/B/C | Haemophilus ducreyi – (HD) | Haemophilus influenzae |
| Herpes simplex Virus 1– (HSV-1) | Herpes simplex Virus 2 – (HSV-2) | Human Bocavirus 1/2/3 | Human Metapneumovirus – hMPV |
| Influenza A/B | KRAS – 16 mutations | LDLR – 38 mutations | Legionella pneumophila |
| Moraxella catarrhalis | Mycoplasma genitalium – (MG) | Mycoplasma hominis – (MH) | Mycoplasma pneumoniae |
| Neisseria gonorrhoea – (NG) | Parainfluenza Virus 1/2/3/4 | PCSK9 – 1 mutation | PIK3CA – 3 mutations |
| Respiratory Syncytial Virus a – RSVa | Respiratory Syncytial Virus b – RSVb | Rhinovirus A/B | Streptococcus pneumoniae |
| Treponema pallidum – (TP) | Trichomonas vaginalis – (TV) | Ureaplasma urealyticum – (UU) | |
Veterinary Residues / Food Diagnostics
| 17β-Clostebol | 5-hydroxy Flunixin | Aflatoxin B1 | Aflatoxin G1/G2 |
| Aflatoxin M1 | AHD | Amikacin/Kanamycin | Amino Benzimidazoles |
| Amoxicillin | AMOZ | Amphenicols | Ampicillin |
| AOZ | Apramycin | Avermectins | Bacitracin |
| Baquiloprim | Benzimidazoles | Beta-agonists | Beta-Lactams |
| Boldenone | Cefapirin | Cefoperazone | Cefquinome |
| Ceftiofur | Cefuroxime | Cephalexin | Cephalonium |
| Chloramphenicol | Chlormadinone | Clopidol | Cloxacillin |
| Corticosteroids | Dapsone | Decoquinate | Deoxynivalenol |
| Dexamethasone | Diacetoxyscirpenol | Diclazuril | Dicloxacillin |
| Dihydrostreptomycin | Ergot Alkaloids | Erythromycin | Ethinylestradiol |
| Fumonisins | Gentamicin | Gestagens | Halofugine |
| Hygromycin B | Imidocarb | Kanamycin | Lasalocid |
| Levamisole | Lincomycin | Lincosamides | MaduramicinG |
| Melamine | Meloxicam | Metamizole | Methyltestosterone |
| Monensin | Moxidectin (MXD) | Nandrolone | Neomycin/Paromomycin |
| Nicarbazin | Nitroimidazoles | Nitroxynil | Novobiocin |
| Ochratoxin A | Oxacillin | Paxilline | Penicillin G |
| Penicillin V | Phenylbutazone | Pirlimycin | Polymixins |
| Quinolones | Ractopamine | Rifaximin | Robenidine |
| Salinomycin | SEM | Spectinomycin | Spiramycin |
| Spiramycin/Josamycin | Stanozolol | Stilbenes | Streptomycin |
| Sulfaguanidine | Sulfamethazine | Sulphachlorpyridazine | Sulphadiazine |
| Sulphadimethoxine | Sulphadoxine | Sulphamerazine | Sulphamethazine |
| Sulphamethizole | Sulphamethoxazole | Sulphamethoxypyridazine | Sulphapyridine |
| Sulphaquinoxaline | Sulphathiazole | Sulphisoxazole | Sulphonamides |
| T2 toxin | Tetracyclines | Thiabendazole | Thiamphenicol |
| Tobramycin | Tolfenamic Acid | Toltrazuril | Trenbolone |
| Triclabendazole | Trimethoprim | Tylosin | Tylosin B/Tilmicosin |
| Virginiamycin | Virginiamycin M1 | Zearalenone | Zeranol |
Evidence MultiSTAT – Biochip Immunoanalyser
Fast. Fully Automated. Versatile.
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. It requires a small sample volume and generates results in less than 20 minutes. The process from sample entry to results can be completed in 3 simple steps, with minimum room for human error. The process is designed to make set up and analysis as quick, simple and reliable as possible.
The MultiSTAT offers a very simple drug screening solution to those who have no knowledge of laboratory procedures through combining simplicity with cutting-edge innovation. It is this innovative technology that enables the MultiSTAT to be easy to use, yet extremely powerful.
- Fully automated benchtop immunoanalyser
- Up to 132 tests per hour
- Results generated in 17 minutes
- Up to 44 analytes screened per biochip
- 3 steps from sample entry to results
- No laboratory / laboratory experience required to operate
- Suitable for use in a range of laboratory and non-laboratory settings
- 59cm (H) x 54cm (D) x 57cm (W)
Evidence MultiSTAT Test Menu
| AB-PINACA | Benzodiazepines II | EtG | Ketamine | TCA |
| Amphetamine | Buprenorphine | Fentanyl | LSD | UR-144 / XLR II |
| a-PVP | BZG/Cocaine | Methadone | Opiates | JWH-018 |
| Barbiturates | Cannabinoids | Methamphetamine | Oxycodone | 6 MAM |
| Benzodiazepines I | Dextromethorphan | Creatinine | Tramadol | PCP |